Section Arrow
URGN.NASDAQ
- UroGen Pharma Ltd
Quotes are at least 15-min delayed:2026/07/17 12:50 EDT
Regular Hours
Last
 41
+1 (+2.50%)
Day High 
41.88 
Prev. Close
40 
1-M High
41.36 
Volume 
535.41K 
Bid
40.91
Ask
41.1
Day Low
39.5 
Open
39.815 
1-M Low
32.17 
Market Cap 
1.95B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 38.85 
20-SMA 37.01 
50-SMA 31.97 
52-W High 41.36 
52-W Low 15.04 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.74/1.48
Enterprise Value
2.08B
Balance Sheet
Book Value Per Share
-2.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
109.79M
Operating Revenue Per Share
1.49
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ATAIAtaiBeckley Inc7.19+0.04+0.56%-- 
IOVAIovance Biotherapeutics4.975+0.315+6.76%-- 
RXRXRecursion Pharmaceuticals2.9799-0.0401-1.33%-- 
LIMNLiminatus Pharma Inc0.125-0.0227-15.37%-- 
KLRSKalaris Therapeutics Inc5.41+0.8+17.35%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.